Arcturus Therapeutics
ARCT
24 hedge funds and large institutions have $60.5M invested in Arcturus Therapeutics in 2014 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 8 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
20% more funds holding
Funds holding: 20 → 24 (+4)
16% more capital invested
Capital invested by funds: $52.2M → $60.5M (+$8.34M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
+$6.57M |
| 2 |
JP Morgan Chase
New York
|
+$4.43M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$923K |
| 4 |
B
Bailard
Foster City,
California
|
+$741K |
| 5 |
SIM
Spark Investment Management
New York
|
+$570K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
|
-$2.86M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.28M |
| 3 |
SC
Sophrosyne Capital
New York
|
-$998K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$224K |
| 5 |
RFC
Russell Frank Company
Seattle,
Washington
|
-$100K |
ARCT Hedge Fund Activity: Q1 2014 in Review
24 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q1 2014, worth a combined $60.5M — up 16% from $52.2M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ARCT positions and 8 closed out — a net gain of 4 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Verition Fund Management, opening a new position worth an estimated $6.57M. The largest seller was Austin W. Marxe & David M. Greenhouse, cutting an estimated $2.86M.
- 24 institutional investors held Arcturus Therapeutics (ARCT) as of Q1 2014, up from 20 in Q4 2013.
- Funds reported $60.5M of Arcturus Therapeutics stock for Q1 2014, up 16% quarter-over-quarter.
- 12 funds opened new Arcturus Therapeutics positions in Q1 2014 and 8 closed out, a net change of +4 holders.
- The largest Arcturus Therapeutics buyer in Q1 2014 was Verition Fund Management, an estimated $6.57M added.
- The largest Arcturus Therapeutics seller in Q1 2014 was Austin W. Marxe & David M. Greenhouse, an estimated $2.86M sold.
Based on aggregated 13F filings for Q1 2014.